At Alexion, we commit ourselves every day to delivering on our mission of serving people living with rare diseases. This is especially important during a global health crisis like the current COVID-19 pandemic. We remain focused on continuing to serve the patients who rely on us, as well as protecting the health and safety of our employees and the communities in which we live and work.
Commitment to Patients
The resilience of patients and their families is our inspiration, and the safety of those receiving our medicines and participating in our clinical trials remains paramount. Alexion's goal is always to manage a robust supply chain that delivers medicines that are secure, sterile and meet our rigorous quality standards. In addition, due to the life-saving nature of our medicines, we strive to maintain sufficient inventory levels to ensure their supply to the patients who rely on them. We have taken proactive measures to mitigate the risk of potential interruptions in supply, and we are continuing to actively monitor this dynamic and rapidly evolving situation worldwide.
Alexion is committed to doing our part to protect our own safety and the safety of those around us by being smart in our actions and minimizing any potential interactions that could contribute to the spread of the virus and place additional burden on our healthcare systems. The patients and families we serve, and their care teams, are at the front of our minds as we work to redefine what it means to effectively support them through increased virtual means in this dynamic and challenging environment.
Alexion's approach to responding to COVID-19 reflects the following priorities:
- Protecting patient and customer safety and medicine supply continuity;
- Ensuring safety and a sense of security for people who work at Alexion;
- Safeguarding our manufacturing, distribution and research facilities;
- Maintaining the integrity of our clinical trials and commitment to data quality;
- Responsibly supporting our community and local healthcare systems; and
- Remaining nimble and responsive to the ever-changing situation while always remaining true to our core values.
Patients Taking Alexion Medicines
We understand that you may have questions about COVID-19 and your medicine. If you are taking an Alexion medicine, please first speak with your doctor about any questions you have. If you have additional questions, and are in the U.S., please call OneSource at 1-888-765-4747. If you live outside the U.S., local contact information by country can be found here.
If you are a healthcare provider with questions about COVID-19 and Alexion medicines, please contact Alexion’s Medical Information team at MedInfo@alexion.com (global) or 1-888-765-4747 (U.S.).
Interactions with Global Health Authorities
Alexion is in discussions with global health authorities and governments, including the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense (DoD), regarding possible options to investigate SOLIRIS® (eculizumab) in COVID-19 in order to better understand the role of terminal complement inhibition in managing the severe pneumonia associated with the virus. While these discussions are underway, at the request of physicians, and in accordance with relevant national regulatory agencies, Alexion has provided SOLIRIS as an experimental emergency treatment for a small number of patients with COVID-19 infection and severe pneumonia. More information on submitting requests can be found here. However, given that SOLIRIS is not approved for COVID-19 and there have not been any clinical trials to date, we cannot speculate on the outcome of our ongoing discussions, possible next steps or the potential role or efficacy of SOLIRIS in COVID-19.
More information: Company Statement
If anything, living with PNH has made me appreciate my time even more, and given me more drive to get back to doing what I love to do.”JOE LIVING WITH PNH